Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (11351)	11/18/1997 6:33:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Andy, I haven't seen details, but the press release indicates that the milestone payment is tied to certain indications, which could mean that sales have to reach a certain level, or additional approvals have to be achieved. It seems that if the sales are below a given level, LLY isn't all that interested (although the sales could do wonders for LGND's bottom line), and the indications should coincide with LGND's areas of interest (which would be cancer and psoriasis since both Targretin and Panretin are in trials for those indications).